Introduction
The different types of renal tumors are caused by various specific genomic alterations determining their phenotype and their aggressiveness. Oncocytomas are benign tumors characterized by dense cytoplasmic accumulation of mitochondria (1) the cause of which remains to be elucidated. They also occur in thyroid gland (H urtle cell tumor), salivary gland and in adrenal gland (2) . Renal oncocytomas originate from the collecting duct (3) . They are associated with heterogeneous chromosomal changes: a first subgroup includes tumors with frequent loss of chromosomes Y and 1, another one includes translocations comprising the breakpoint region 11q13, and a third subgroup comprises tumors with various genetic abnormalities such as monosomies, trisomies and loss of heterozygosity in several chromosomes. Mutations of the tumor suppressors VHL or p53 are infrequent or absent (1) . In spite of this genetic variability, phenotypes are remarkably similar, with a low mitotic index, leading in the quiescent kidney parenchyma to a clear-brown tumor and, under the microscope, a granular, eosinophilic cytoplasm stacked up with mitochondria (1, 4) .
The most frequent tumors in kidney are clear cell renal cell carcinomas (CCRCCs), originating from the proximal tubule. Their common feature is abnormality of the tumor suppressor protein pVHL (von Hippel-Lindau) (1, 5) , a ubiquitin-ligase down-regulating HIF-1 (the hypoxia-inducible transcription factor) (6) . Their metastatic capacity and resistance to antimitotic drugs make them very aggressive (7) . Chromophilic (or tubulopapillary) tumors are renal cell carcinomas less aggressive than CCRCCs, and also originate from the proximal tubule. They are due to a constitutive activation of the protooncogene product c-MET, the hepatocyte growth factor receptor (8) .
When kidney tumors were tested for their oxidative phosphorylation (OXPHOS) capacity, a striking inverse correlation was found between several OXPHOS enzymes (activity and protein content) and the aggressiveness of the tumor type (9) . Namely, complex IV (cytochrome c oxidase, or COX), complex II (succinate dehydrogenase), complexes II and III and complex V (ATPase/ATP-Synthase), were negatively correlated with the seriousness of the tumor type and with its F uhrman's grade. All these activities were decreased in malignant carcinomas and increased in the benign oncocytomas. The high mtDNA and citrate synthase contents in oncocytomas reflected their dense accumulation of mitochondria.
The cause of mitochondria accumulation in oncocytomas was so far unknown, but a similar feature has already been observed in mitochondrial pathologies. In fact, aggregations of abnormal mitochondria under the sarcolemma of type I fibers has been described as early as 1962 by Luft et al. (10) . The proliferation of these abnormal mitochondria has been named ragged red fibers' (RRF) (11) . RRF is a characteristic histological feature of skeletal muscle presenting mtDNA deletions, duplications or mitochondrial tRNA point mutations and it is generally accepted that the proliferation of mitochondria in this pathology is initiated by a deficient mitochondrial ATP synthesis, and followed by an up-regulation mechanism increasing the transcription of nuclear genes coding for mitochondrial proteins (12) . Therefore, the question was whether accumulated mitochondria in renal oncocytomas are fully functional or if they are the result of an attempt to restore some deficiency. In thyroid oncocytomas, Savagner et al. (13) have shown that oxygen consumption is defective in spite of the mitochondria accumulation. In our previous studies (9), complex I activity had not been analyzed, but two dimensional-PAGE performed on one oncocytoma suggested that complex I might be decreased while all other OXPHOS complexes were increased.
In the present work, we focused on the analysis of respiratory chain complex I, measuring its NADH dehydrogenase activity, the complex I protein content, and the immunoreactivity of its 75 kDa subunit in oncocytomas, in chromophilic tumors, in CCRCCs, and in their respective adjacent normal tissue. The results confirm that there is a specific deficiency of complex I in oncocytomas.
Materials and methods

Biopsies
Kidneys were surgically removed for renal tumor. After examination by the pathologist, normal cortex and tumor tissue samples (100±400 mg) were dissected and immediately frozen in liquid nitrogen and stored until utilization. Tumor grades were determined according to the Fuhrman's classification (4).
NADH dehydrogenase enzyme activity
Frozen tissue samples (50±150 mg) were minced on a cooled glass plate and then homogenized with a Teflon or a glass Potter in 200±500 ml of medium containing 66 mM sucrose, 222 mM mannitol, 10 mM HEPES buffered with KOH at pH 7.4, 1.2 mg/ml bovine serum albumin (fatty acid free), 1.1 mM EDTA, 0.04 mM pepstatin, and 0.4 mM epsilon-amino caproic acid. The remaining debris were sedimented by a pulse centrifugation and the supernatant homogenate was passed through a 16-gauge needle. NADH dehydrogenase determinations were performed using the spectrophotometric methods of Rustin et al. (14) . Briefly, 1±20 ml homogenate were osmotically lysed in 0.8 ml water for 3 min at 37 C, then 0.2 mM NADH in 10 mM Tris±HCl, pH 8.0, 0.05 mM decylubiquinone and 0.3 mM KCN were added. The total NADH: decylubiquinone oxidoreductase activity was recorded at 340 nm for 42 min, then the appropriate inhibitor was added to the cuvette. Mitochondrial complex I activity was inhibited by 0.3 mM rotenone. In preliminary studies, this concentration was found to be the lowest dose able to induce maximal inhibition of NADH dehydrogenase in normal kidney cortex, this tissue containing one of the largest amounts of mitochondria. Non-mitochondrial NADH oxidoreductases were also determined using another specific inhibitor of the respiratory chain, KCN. NADH:O 2 oxidoreductase activity was recorded in the absence of decylubiquinone and of KCN. The contributing mitochondrial activity related to endogenous cytochrome c was then inhibited by 0.3 mM KCN.
Citrate synthase. Citrate synthase activity was determined according to Srere (15) .
Protein content. Protein content was determined using the Bradford Coomassie reagent from Biorad TM .
Two-dimensional resolution of the OXPHOS complexes
Crude mitochondria from 10 mg of kidney (wet weight) were solubilized by dodecylmaltoside and the native OXPHOS complexes separated by Blue Native-PAGE using a 5±13% acrylamide gradient gel, as described previously (16) . The subunits of the complexes were then resolved in a second dimension by a 16% acrylamide, Tricine±SDS gel, and Coomassie stained (16) .
Immunological detection of the 75 kDa subunit
Five percent each of the crude mitochondrial extracts used for BN-PAGE and two-dimensional resolution as described above were used for SDS±PAGE corresponding to 0.5 mg kidney tissue (or~15 mg extracted mitochondrial protein). The mitochondrial proteins were resolved by a 10% acrylamide SDS gel according to Laemmli (17) , and transferred to PVDF membranes according to Sch agger (18) . The PVDF membrane was incubated first with a polyclonal rabbit antibody against the 75 kDa subunit of bovine complex I, and secondly with a peroxidase-labeled anti-rabbit antibody. The peroxidase activity was then monitored using the ECL reagent according to the manufacturer's instructions (Amersham Pharmacia Biotech TM , Uppsala, Sweden).
Results
Specific decrease of mitochondrial complex I in oncocytomas
The enzyme activity of respiratory complex I was determined as the NADH:decylubiquinone reductase activity that could be suppressed by 0.3 mM rotenone. Figure 1 shows that complex 1 activity was decreased in each of the five tested oncocytomas.
Since this decrease contrasted with the increase of other OXPHOS enzyme activities and accumulation of mitochondria (3,9), we determined the citrate synthase activity in the same tumors as a measure for mitochondria content. The results confirmed the inverse relationship of citrate synthase (increased) and of complex I (decreased) in each of the oncocytoma tissues tested ( Figure 1) . Similarly, we found decreased complex I protein amounts in all tested oncocytomas, when mitochondria were analyzed by two-dimensional PAGE, again in stark contrast to the increase in other complexes such as cytochrome oxidase (complex IV) or ATP synthase (complex V) (Figure 2 ). To better visualize the reduction of complex I in oncocytomas, we used an antibody against the 75 kDa subunit of complex I for immunodetection. A marked decrease of the 75 kDa subunit again indicated complex I deficiency in each of the seven tested oncocytomas (Figure 3) .
Altogether a pronounced complex I deficiency was evident in all oncocytomas tested (n 8) although the enzymatic, electrophoretic or immunologic analyses could not be performed in some of the patients because of the small size of some samples.
Complex I activity in different types of renal tumors and in adjacent tissues
Mitochondrial complex I enzyme activity was measured in several types of renal tumors and compared with non-tumoral tissue from the same kidneys, termed normal tissue. The results are shown in Figure 4 and in Table I .
In normal tissue of tumor-bearing kidneys, the rotenonesensitive NADH:decylubiquinone oxidoreductase activities were (nmol min À1 mg protein À1 ): 50.9 AE 15.2 (n 5) in tissues adjacent to low grade CCRCCs, 79.3 AE 67.2 (n 5) in tissues adjacent to high grade CCRCCs, 50.7 AE 11.2 (n 3) in the vicinity of chromophilic renal cell carcinomas, and only 21.2 AE 6.1 (n 5) in tissues adjacent to renal oncocytomas (Figure 4) . Therefore, there is a significant reduction of NADH dehydrogenase in the vicinity of oncocytomas (P 5 0.05, according to the Kruskall and Wallis' non-parametric test). Similarly, the CN-sensitive NADH:O 2 oxidoreductase activity was reduced in tissues adjacent to oncocytomas (P 5 0.05, Kruskall and Wallis' test) ( Table I) . Fig. 1 . Decrease of complex I activity in oncocytomas. Mitochondrial complex I (rotenone-sensitive NADH:decylubiquinone oxidoreductase) is decreased whereas citrate synthase used as a marker for mitochondria content is increased in tumor tissues. The enzyme activities are expressed as the log of the ratio of tumor tissue activity and normal counterpart activity (nmol min À1 mg protein À1 ). Bars represent the data for individual patients. The mean values AE SD are inserted. Fig. 2 . Two-dimensional resolution of OXPHOS complexes from oncocytomas by Blue Native PAGE/SDS±PAGE. Mitochondria were extracted from 10 mg of frozen tissue from four oncocytomas (right) and from their four normal counterparts (left) and were submitted to two-dimensional PAGE, firstly under nondenaturing conditions (horizontally), and secondly under SDS-denaturing conditions separating the protein subunits (vertically). The location of complex I is indicated by the boxed area. The largest and most intensely stained complex I subunits (75, 51 and 42 kDa) were detected in all normal tissues adjacent to oncocytoma tissue (left) but were below the detection limit in all oncocytomas (right). (A±D) correspond to oncocytoma patients 3 and 4, and to new patients 5 and 6.
Oncocytoma and complex I
In tumor samples, the rotenone-sensitive, NADH:decylubiquinone oxidoreductase activity was decreased in each of the 18 samples tested from the four types of renal tumors. (Figures 3 and 5) , in oncocytomas and in malignant renal cell carcinomas.
These results showed that, in contrast with the parallel decrease of all OXPHOS complexes in renal carcinomas (9 and this work), there is an isolated complex I deficiency in oncocytomas.
Discussion
This work shows for the first time that one of the OXPHOS complexes, complex I, is selectively and constantly decreased in renal oncocytomas. This comes in stark contrast to the Fig. 3 . Decreased amounts of the 75 kDa subunit of complex I in oncocytomas. After separating the mitochondrial proteins by one-dimension SDS±PAGE and electroblotting, the 75 kDa subunit of complex I was immunodetected in tumor tissue (T) and in their normal counterpart (N) from the same kidney. The identification numbers of the different patients are the same as in Figures 1 and 2 , except for number 7 corresponding to a new patient. parallel decrease of respiratory chain complexes observed in other, malignant, renal tumors. Since complex I is deficient, oxidative phosphorylation cannot be fully functional, although all other OXPHOS complexes were found to be increased in oncocytomas. In agreement, decreased oxygen consumption and defective mitochondrial ATP production was reported by Savagner et al. (13) in another type of oncocytoma, the thyroid oxyphilic tumors. Hence the induction of mitochondrial biogenesis, of citrate synthase and of mitochondrial DNA/nuclear DNA in oncocytomas (3, 4, 9) is not likely to be a primary event, but rather a response mechanism attempting to compensate for inefficient oxidative phosphorylation. It is reminiscent of the increased biogenesis of abnormal mitochondria occurring in response to alterations of mtDNA in mitochondrial pathologies (12) and suggests that the decrease of complex I protein and activity in renal oncocytomas could be causal to the accumulation of mitochondria, the hallmark of this relatively benign tumor.
The correlation between complex I deficiency and tumoral growth arises two major questions. Is tumor formation due to the defective complex I or to some other unidentified alteration? And how can such a heterogeneous group of genetic alterations as that observed in oncocytomas (1, 19) be related to the observed unique complex I deficiency?
The respiratory chain NADH dehydrogenase is the largest OXPHOS complex. It is L-shaped and made up of at least 45 different subunits as reviewed by Kerscher et al. (25) . Although the mechanism of electron transport and proton translocation by complex I are not elucidated so far, all genes coding for the human subunits have been sequenced, including the seven genes encoded by the mitochondrial DNA and the 36 nuclear genes (23) . Genetic alteration in any of these subunits could result in the same complex I deficiency if the modified protein could not be used for assembly of the complex, or if the stability of the complex was disturbed. Factors, which are very likely required for assembly of complex I but not found in the assembled complex, are further candidates for genetic alterations that would also result in complex I deficiency.
Previous studies (26) provided no evidence that mtDNA alterations were responsible for the pathogenesis of oncocytomas. For example, a specific deletion (`common deletion'), which can be observed in mitochondrial disorders, was no more frequent in tumors than in normal tissues. In addition the mtDNA size estimated by segmental amplification (26) or by Southern blot (9) was found to be normal indicating that large mtDNA deletions are not commonly present in these tumors. However systematic sequencing of mitochondriaencoded complex I genes has never been performed in oncocytomas.
Nuclear gene sequences encoding and regulating the expression of complex I subunits and of their known assembly factors have also not been analyzed in oncocytomas so far. However, a great number of nuclear chromosomal rearrangements have been described (1) . As none of these different genetic alterations was found in all or even a majority of the tested oncocytomas (1, 26) , it seems possible that they end at a common unique deficiency of complex I assembly, by affecting one of the 36 nuclear genes coding for complex I subunits that are scattered over many different chromosomes (23) . Sequencing the 43 genes encoding complex I in several patients bearing oncocytomas represents a hard task but is now under progress in our laboratory. Alternatively, a unique, genetic defect specific to oncocytomas could have remained undetected until now. In the latter case, the observed nuclear genome alterations would be additional defects, since additional variable genetic events are frequent in other adult renal tumor types (1) . The genetic analysis of familial forms of oncocytomas (19, 27) should bring out important information to address this question. Moreover, it might be advisable to search for an additional alteration not in the tumors itself but in adjacent areas, since tissue adjacent to oncocytomas differed from normal renal parenchyma with respect to complex I activity. This NADH oxidation, expressed in nmol min À1 mg protein À1 (mean AE SD), was first measured in the absence of exogenous decylubiquinone and of KCN as described in Materials and methods, and secondly after addition of KCN in the cuvette. The CN-sensitive activity represents the difference between the rates measured before and after KCN addition. CCRCC: clear cell renal cell carcinoma, low-(low) or high-grade (high). alteration is detectable in enzyme activity but not in protein content (see Figures 2 and 4) , and is not associated with mitochondria accumulation. It could be induced by oncocytoma, but more probably represents an early event. Indeed, it is again restricted to complex I activity since the other OXPHOS activities were not decreased in tissues adjacent to oncocytomas (9) . Identification of the gene(s) involved in tumor pathogenesis could help to understand whether complex I deficiency is a required step in tumoral growth of oncocytomas.
Complex I decrease could be caused by a side effect of another alteration also inducing a loss of growth control by an independent mechanism. However, it seems feasible that complex I deficiency itself could cause directly or indirectly the increase of cell growth since other genetic defects affecting mitochondria have been recently found to be associated with benign tumors. A first example is fumarate hydratase familial impairment, which could cause an imbalance of NADH supply to the respiratory chain, and which is assumed to be a true tumor suppressor gene in familial uterine fibroids (28) . A second example is the familial impairment of several subunits of respiratory chain complex II, which leads to a unique phenotype of paraganglioma (29, 30) . The common feature of these tissues (kidney, uterine myometrium and parasympathetic ganglia) is their low rate of renewal. Interestingly, both myometrium and kidney are susceptible to develop tumors caused by alteration of a cell cycle inhibitor and tumor suppressor gene, TSC-2 (31, 32) , showing that they share at least in part the same pathway of cell cycle regulation. If genetic defects could be disclosed in the genes encoding the complex I subunits and if reproducing these defects in an ex vivo model could increase mitochondrial biogenesis and tumorigenic capacity, it would be a third example for a defect associated with mitochondrial ATP production that induces a benign tumoral growth in a quiescent tissue type.
